Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology

Volumn 76, Issue 3, 2017, Pages 405-417

  Blauvelt, Andrew ^a   Papp, Kim A ^b   Griffiths, Christopher E M ^c   Randazzo, Bruce ^d,e   Wasfi, Yasmine ^d   Shen, Yaung Kaung ^d   Li, Shu ^d   Kimball, Alexa B ^f  

^a OREGON MEDICAL RESEARCH CENTER   (United States)

^b K Papp Clinical Research and Probity Medical Research   (Canada)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

adalimumab; efficacy; guselkumab; hand and foot psoriasis; nail psoriasis; psoriasis; safety; scalp psoriasis; VOYAGE 1; VOYAGE 2

Indexed keywords

ADALIMUMAB; GUSELKUMAB; PLACEBO; DERMATOLOGICAL AGENT; INTERLEUKIN 23; MONOCLONAL ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; MALE; NON MELANOMA SKIN CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SUDDEN CARDIAC DEATH; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-23; MALE; MIDDLE AGED; PLACEBOS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 85008701919     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.11.041     Document Type: Article

References (46)

1. 1 World Health Organization. Global report on psoriasis. Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf. Accessed May 31, 2016.
2. 2 Kragballe, K., Menter, A., Lebwohl, M., et al. Long-term management of scalp psoriasis: perspectives from the international psoriasis council. J Dermatol Treat 24 (2013), 188–192.
3. 3 Tan, E.S.T., Chong, W.-S., Liang Tey, H., Nail psoriasis: a review. Am J Clin Dermatol 13 (2012), 375–388.
4. 4 Chung, J., Callis Duffin, K., Takeshita, J., et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol 71 (2014), 623–632.
5. 5 Wozel, G., Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 26 (2008), 448–459.
6. 6 Nestle, F.O., Kaplan, D.H., Barker, J., Psoriasis. N Engl J Med 361 (2009), 496–509.
7. Hl7 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007), 648–651.
8. 8 Lyakh, L., Trinchieri, G., Provezza, L., et al. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 226 (2008), 112–131.
9. 9 Reich, K., Nestle, F.O., Papp, K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 366 (2005), 1367–1374.
10. 10 Papp, K.A., Tyring, S., Lahfa, M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005), 1304–1312.
11. 11 Menter, A., Tyring, S.K., Gordon, K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2008), 106–115.
12. 12 Leonardi, C.L., Kimball, A.B., Papp, K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371 (2008), 1665–1674.
13. 13 Papp, K.A., Langley, R.G., Lebwohl, M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 (2008), 1675–1684.
14. 14 Langley, R.G., Elewski, B.E., Lebwohl, M., et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 371 (2014), 326–338.
15. 15 Griffiths, C.E., Reich, K., Lebwohl, M., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials. Lancet 386 (2015), 541–551.
16. 16 Lebwohl, M., Strober, B., Menter, A., et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 373 (2015), 1318–1328.
17. 17 Kopp, T., Riedl, E., Bangert, C., et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 521 (2015), 222–226.
18. 18 Sofen, H., Smith, S., Matheson, R.T., et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 133 (2014), 1032–1040.
19. 19 Gordon, K.B., Callis Duffin, K., Bissonnette, R., et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 373 (2015), 136–144.
20. 20 Krueger, J.G., Ferris, L.K., Menter, A., et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 136 (2015), 116–124.
21. 21 Papp, K., Thaci, D., Reich, K., et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol 173 (2015), 930–939.
22. 22 Teng, M.W.L., Bowman, E.P., McElwee, J.J., et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nature Med 21 (2015), 719–729.
23. 23 Reich, K., Armstrong, A.W., Foley, P., et al. Efficacy and safety of guselkumab, an anti-IL-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate-to-severe psoriasis with randomized withdrawal and retreatment: results from the Phase 3, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 76 (2017), 418–431.
24. 24 Fredriksson, T., Pettersson, U., Severe psoriasis – oral therapy with a new retinoid. Dermatologica 157 (1978), 238–244.
25. 25 Rich, P., Scher, R., Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 49 (2003), 206–212.
26. 26 Finlay, A.Y., Khan, G.K., Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994), 210–216.
27. 27 Mathias, S.D., Feldman, S.R., Crosby, R.D., et al. Measurement properties of a patient reported outcome measure assessing psoriasis severity: the Psoriasis Symptoms and Signs Diary. J Dermatol Treat 27 (2016), 322–327.
28. 28 Feldman, S.R., Mathias, S.D., Schenkel, B., et al. Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the Psoriasis Symptoms and Signs Diary. J Dermatol Surg 20 (2016), 19–26.
29. 29 Revicki, D.A., Willian, M.K., Menter, A., et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 216 (2008), 260–270.
30. 30 Viswanathan, H.N., Chau, D., Milmont, C.E., et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatol Treat 26 (2015), 235–239.
31. 31 Blauvelt, A., Lebwohl, M.G., Bissonnette, R., IL-23/IL-17A dysfunction phenotypes Inform possible clinical effects from anti-IL-17A therapies. J Investig Dermatol 135 (2015), 1946–1953.
32. 32 Aggarwal, S., Ghilardi, N., Xie, M.-H., et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of Interleukin-17. J Biol Chem 278 (2003), 1910–1914.
33. 33 Wilson, N.J., Boniface, K., Chan, J.R., et al. Development, cytokine profile and function of human interleukin 17–producing helper T cells. Nature Immunol 8 (2007), 950–957.
34. 34 Ness-Schwickerath, K.J., Jin, C., Morita, C.T., Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells. J Immunol 184 (2010), 7268–7280.
35. 35 Villanova, F., Flutter, B., Tosi, I., et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Investig Dermatol 134 (2014), 984–991.
36. 36 Ward, N.L., Umetsu, D.T., A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells. J Investig Dermatol 134 (2014), 2305–2307.
37. 37 Teunissen, M.B.M., Marius Munneke, J., Bernink, J.H., et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR+ ILC3 in lesional skin and blood of psoriasis patients. J Investig Dermatol 134 (2014), 2351–2360.
38. 38 Blauvelt, A., New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A, and TGF-β1. Expert Rev Dermatol 2 (2007), 69–78.
39. 39 Humira [package insert], 2002, Abbott Laboratories, Chicago, IL.
40. 40 Enbrel [package insert], 1998, Amgen Inc, Thousand Oaks, CA.
41. 41 Remicade [package insert], 1998, Janssen Biotech Inc, Horsham, PA.
42. 42 Cosentyx [package insert], 2015, Novartis Pharmaceuticals Corp, East Hanover, NJ.
43. 43 Taltz [package insert]. 2016, Eli Lilly and Company, Indianapolis, IN.
44. 44 Papp, K., Gottlieb, A.B., Naldi, L., et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 14 (2015), 706–714.
45. 45 Kimball, A.B., Papp, K.A., Wasfi, Y., et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 27 (2013), 1535–1545.
46. 46 Langley, R.G., Lebwohl, M., Krueger, G.G., et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 172 (2015), 1371–1383.